GlobeNewsWire
06 Mar 2026, 13:30 UTC · 36w ago
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Impact · against what's priced in
Solid Biosciences is introducing potential catalysts through upcoming data presentations on SGT-003 and SGT-212. The focus on reducing liver toxicity and improving cardiac tropism addresses the primary risks associated with AAV gene therapies, providing a pathway for the company to validate its 'best-in-class' claims.
- SLDB+0.60
No priced-in read yet





